Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-24
Target enrollment:
Participant gender:
Summary
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.
Phase:
PHASE3
Details
Lead Sponsor:
Unity Health Toronto
Collaborators:
Canadian Institutes of Health Research (CIHR) Health Canada